Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimco Realty Corporation (HC) Common Stock vs Tango Therapeutics Inc. — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.48 (market cap $15.06B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Kimco Realty Corporation (HC) Common Stock is far larger — about 4× Tango Therapeutics Inc.'s market cap, and Kimco Realty Corporation (HC) Common Stock pays a 4.99% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| KIM | TNGX | |
|---|---|---|
Market Cap | $15.06B | $3.75B |
Volume | 6,246,987 | 9,619,106 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $32.90 |
52-Week Low | $19.78 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $23.22B | $2.77B |
Dividend Yield | 4.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KIM trades at $22.45, up 0.58% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Fundamentals show robust profitability with a 27.76% net income margin and a P/E of 26.1. Analyst consensus is a Buy with a $26.09 price target, though technical indicators suggest near-term caution.
The outlook for KIM is mixed; strong fundamentals and positive analyst sentiment support upside, but technical bearishness and macroeconomic risks pose challenges. Investment opportunity lies in its high dividend yield and earnings growth, while risks include market volatility and real estate sector headwinds. The stock's performance will hinge on upcoming earnings and broader economic conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kimco Realty Corporation (HC) Common Stock
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
